Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases

PartnershipTfR1 CapX™Positive

AI Analysis

Summary

Apertura Gene Therapy was selected as part of a consortium led by Broad Institute to receive ARPA-H THRIVE Program funding for developing gene therapies targeting rare childhood diseases using its TfR1 CapX™ CNS-targeted AAV capsid technology.

Outcome Details

Apertura Gene Therapy selected for ARPA-H THRIVE Program consortium to develop gene therapies for rare childhood diseases using TfR1 CapX™ CNS-targeted AAV capsid for base and prime gene editing programs

Importance:6/10

Sentiment:

0.70

gene therapyAAV capsidrare diseasesCNS targetinggovernment fundingbase editingprime editing

Related Companies

$GBIO $HIT

Read the original article

Published by PR Newswire Clinical Trials on July 23, 2026 4:00 PM

Read Original